Quantified Biology

Executive Summary

Quantified Biology, founded in 2020 in Israel, is a private biotech company leveraging quantitative biology, multi-omics data integration, and machine learning to accelerate drug discovery and target validation. Its platform aims to build predictive models for therapeutic candidates, focusing on high-throughput screening and data-driven decision-making. By integrating genomics, proteomics, and other omics data, the company seeks to de-risk drug development and improve success rates. Though still in the platform stage with no disclosed funding or valuation, Quantified Biology operates at the intersection of AI and biology, a high-growth area attracting significant investment. Its success hinges on demonstrating superior predictive accuracy compared to traditional methods and securing partnerships with pharma or biotech firms. The company's location in Israel's vibrant biotech ecosystem provides access to talent and capital. Given the early stage and lack of public milestones, the conviction is moderate, but the approach holds promise for transforming early-stage drug discovery.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a major pharma company for platform validation40% success
• Q1 2027Publication of a peer-reviewed study demonstrating platform's predictive accuracy50% success
• H1 2027Series A funding round led by top-tier life sciences VC35% success